Journal of Enzyme Inhibition and Medicinal Chemistry最新文献

筛选
英文 中文
Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites. 基于降冰片烯嵌段共聚物的ph响应泛hdac抑制剂(C5)纳米聚合物的设计与合成,以提高C5的溶解度并改善其在前列腺癌部位的靶向递送。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-07-23 DOI: 10.1080/14756366.2025.2530557
Jacob Mathew, Anshul Mishra, Trong-Nghia Le, Jing-Ping Liou, Mei-Jung Lai, Vijayakameswara Rao Neralla
{"title":"Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites.","authors":"Jacob Mathew, Anshul Mishra, Trong-Nghia Le, Jing-Ping Liou, Mei-Jung Lai, Vijayakameswara Rao Neralla","doi":"10.1080/14756366.2025.2530557","DOIUrl":"10.1080/14756366.2025.2530557","url":null,"abstract":"<p><p>This study investigated the incorporation of C5, a pan-HDAC inhibitor, into a norbornene-derived block copolymer with pH-sensitive hydrolysis (PNEG-b-P(Nor-PABA-C5)) to generate NPs for prostate cancer treatment. Amphiphilic PNEG-b-P(Nor-PABA-C5) formed NPs in aqueous environments, with hydrophobic Nor-PABA-C5 monomers in the core and hydrophilic PNEG monomers on the surface. DLS analysis showed a particle size of 122 ± 12 nm with a PDI of 0.35, confirmed by SEM and TEM. TEM imaging revealed spherical morphology, enabling the NPs to transport hydrophobic pan-HDACi drugs to PC-3 tumour sites and facilitate release through hydrolysis under acidic conditions. The NPs exhibited pH-hydrolysis characteristics, with enhanced drug release (61 ± 1.7%) at pH 6.2 compared to pH 7.4 (35 ± 0.8%). MTT assay confirmed antiproliferative effect. Analysis of FITC/(PNEG-b-P(Nor-PABA-C5)) cellular uptake showed increased absorption in prostate tumours. Live/dead cell assays showed loss of viability, with increased red fluorescence and morphological disruption at higher concentrations over 48 and 72 h.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2530557"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Site-selective arylations of nature-inspired flavonoids or steroidal phenols via C-H or O-H activation. 通过C-H或O-H活化的天然类黄酮或甾体酚的位点选择性芳基化。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-07-18 DOI: 10.1080/14756366.2025.2530615
Rebeka Ignácz, Noémi Bózsity, Dénes Unger, Zoltán Kele, István Zupkó, Attila Hunyadi, Marija Gjorgoska, Tea Lanišnik Rižner, Erzsébet Mernyák
{"title":"Site-selective arylations of nature-inspired flavonoids or steroidal phenols <i>via</i> C-H or O-H activation.","authors":"Rebeka Ignácz, Noémi Bózsity, Dénes Unger, Zoltán Kele, István Zupkó, Attila Hunyadi, Marija Gjorgoska, Tea Lanišnik Rižner, Erzsébet Mernyák","doi":"10.1080/14756366.2025.2530615","DOIUrl":"10.1080/14756366.2025.2530615","url":null,"abstract":"<p><p>Phenols are important structural elements of natural products and pharmaceuticals. Due to their versatile chemical transformability, phenols are frequently used building blocks in medicinal chemistry. Their aromatic nature allows directed C(sp<sup>2</sup>)-H functionalisations, especially at the <i>ortho</i> positions. In contrast, <i>meta</i> substitutions are less well known. As a continuation of our recently described metal-catalysed cross couplings, here we report arylations of two nature-inspired phenol derivatives <i>via</i> C-H or O-H activation. A directing group (DG) was introduced onto C-3-<i>O</i> of 13α-oestrone, and the resulting carbamate was subjected to Cu(II)-catalysed <i>meta</i> arylation using diaryliodonium triflates as reagents. As a result, C-1-arylated derivatives were obtained. The arylation of the 1'-<i>O</i>-butyl protoapigenone proceeded regioselectively at C-5-<i>O</i>. The 1-(4-<i>tert</i>-butylphenyl)-13α-oestrone carbamate and all <i>O</i>-arylated protoflavones substantially inhibited the growth of the applied human cancer cell lines and exerted proapoptotic activity on HeLa cells. The 1-(4-<i>tert</i>-butylphenyl)-13α-oestrone proved to be a potent 17β-HSD1 inhibitor.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2530615"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-cell bioluminescence resonance energy transfer (BRET)-based assay uncovers ceritinib and CA-074 as SARS-CoV-2 papain-like protease inhibitors. 基于细胞内生物发光共振能量转移(BRET)的检测发现 Ceritinib 和 CA-074 是 SARS-CoV-2 类木瓜蛋白酶抑制剂。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-08-20 DOI: 10.1080/14756366.2024.2387417
Mei Li, Zhu-Chun Bei, Yongtian Yuan, Baogang Wang, Dongna Zhang, Likun Xu, Liangliang Zhao, Qin Xu, Yabin Song
{"title":"In-cell bioluminescence resonance energy transfer (BRET)-based assay uncovers ceritinib and CA-074 as SARS-CoV-2 papain-like protease inhibitors.","authors":"Mei Li, Zhu-Chun Bei, Yongtian Yuan, Baogang Wang, Dongna Zhang, Likun Xu, Liangliang Zhao, Qin Xu, Yabin Song","doi":"10.1080/14756366.2024.2387417","DOIUrl":"10.1080/14756366.2024.2387417","url":null,"abstract":"<p><p>Papain-like protease (PLpro) is an attractive anti-coronavirus target. The development of PLpro inhibitors, however, is hampered by the limitations of the existing PLpro assay and the scarcity of validated active compounds. We developed a novel in-cell PLpro assay based on BRET and used it to evaluate and discover SARS-CoV-2 PLpro inhibitors. The developed assay demonstrated remarkable sensitivity for detecting the reduction of intracellular PLpro activity while presenting high reliability and performance for inhibitor evaluation and high-throughput screening. Using this assay, three protease inhibitors were identified as novel PLpro inhibitors that are structurally disparate from those previously known. Subsequent enzymatic assays and ligand-protein interaction analysis based on molecular docking revealed that ceritinib directly inhibited PLpro, showing high geometric complementarity with the substrate-binding pocket in PLpro, whereas CA-074 methyl ester underwent intracellular hydrolysis, exposing a free carboxyhydroxyl group essential for hydrogen bonding with G266 in the BL2 groove, resulting in PLpro inhibition.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2387417"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors. 作为 ASK1 抑制剂的喹喔啉衍生物的合成和生物学评价。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-10-21 DOI: 10.1080/14756366.2024.2414382
Xiaorui Han, Pingping Lan, Qianfeng Chen, Hua Liu, Zhongwen Chen, Tiantian Wang, Zengtao Wang
{"title":"Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors.","authors":"Xiaorui Han, Pingping Lan, Qianfeng Chen, Hua Liu, Zhongwen Chen, Tiantian Wang, Zengtao Wang","doi":"10.1080/14756366.2024.2414382","DOIUrl":"10.1080/14756366.2024.2414382","url":null,"abstract":"<p><p>Inhibiting apoptosis signal regulated kinase 1 (ASK1) is an attractive strategy for treating diseases such as non-alcoholic steatohepatitis and multiple sclerosis. Here, we report the discovery of a dibromo substituted quinoxaline fragment containing <b>26e</b> as an effective small-molecule inhibitor of ASK1, with an IC<sub>50</sub> value of 30.17 nM. In addition, the cell survival rate of <b>26e</b> at different concentrations was greater than 80%, especially at 0.4 μM. Its cell survival rate was significantly higher than <b>GS-4997</b>, indicating its good safety in normal human liver LO2 cells. The Oil Red O staining experiment showed that <b>26e</b> decreased the lipid droplets in a dose-dependent manner. Further biochemical analyses revealed that <b>26e</b> could reduce the content of T-CHO, LDL, and TG in FFA-induced LO2 cells, and had the potential to treat non-alcoholic fatty disease. These findings provide a good choice for the future development of ASK1 inhibitors.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2414382"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin B6 inhibits activity of Helicobacter pylori adenylosuccinate synthetase and growth of reference and clinical, antibiotic-resistant H. pylori strains. 维生素 B6 可抑制幽门螺旋杆菌腺苷琥珀酸合成酶的活性以及参考菌株和临床抗生素耐药幽门螺旋杆菌菌株的生长。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-08-16 DOI: 10.1080/14756366.2024.2372734
Marta Ilona Wojtyś, Weronika Maksymiuk, Marta Narczyk, Ante Bubić, Ivana Leščić Ašler, Paweł Krzyżek, Grażyna Gościniak, Elżbieta Katarzyna Jagusztyn-Krynicka, Agnieszka Bzowska
{"title":"Vitamin B6 inhibits activity of <i>Helicobacter pylori</i> adenylosuccinate synthetase and growth of reference and clinical, antibiotic-resistant <i>H. pylori</i> strains.","authors":"Marta Ilona Wojtyś, Weronika Maksymiuk, Marta Narczyk, Ante Bubić, Ivana Leščić Ašler, Paweł Krzyżek, Grażyna Gościniak, Elżbieta Katarzyna Jagusztyn-Krynicka, Agnieszka Bzowska","doi":"10.1080/14756366.2024.2372734","DOIUrl":"10.1080/14756366.2024.2372734","url":null,"abstract":"<p><p>The current therapies against gastric pathogen <i>Helicobacter pylori</i> are ineffective in over 20% of patients. Enzymes belonging to the purine salvage pathway are considered as novel drug targets in this pathogen. Therefore, the main aim of the current study was to determine the antibacterial activity of pyridoxal 5'-phosphate (PLP), an active form of vitamin B6, against reference and clinical strains of <i>H. pylori</i>. Using a broad set of microbiological, physicochemical (UV absorption, LC-MS, X-ray analysis) and <i>in silico</i> experiments, we were able to prove that PLP inhibits adenylosuccinate synthetase (AdSS) from <i>H. pylori</i> by the competition with GTP (IC<sub>50</sub><sup>eq</sup> ∼30 nM). This behaviour was attributed to formation of a Schiff base with a lysine residue (a covalent bond with Lys322 in the GTP binding site of AdSS) and was potentiated by the presence of vitamin C. This antibacterial activity of PLP gives hope for its future use against <i>H. pylori</i>.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2372734"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer's disease. 作为选择性丁酰胆碱酯酶抑制剂治疗阿尔茨海默病的新型抗神经炎吡喃酮-氨基甲酸酯衍生物。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-02-16 DOI: 10.1080/14756366.2024.2313682
Chuanyu Yu, Xueyan Liu, Bingxiang Ma, Jiexin Xu, Yiquan Chen, Chaoxian Dai, Huaping Peng, Daijun Zha
{"title":"Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer's disease.","authors":"Chuanyu Yu, Xueyan Liu, Bingxiang Ma, Jiexin Xu, Yiquan Chen, Chaoxian Dai, Huaping Peng, Daijun Zha","doi":"10.1080/14756366.2024.2313682","DOIUrl":"10.1080/14756366.2024.2313682","url":null,"abstract":"<p><p>Butyrylcholinesterase (BuChE) and neuroinflammation have recently emerged as promising therapeutic directions for Alzheimer's disease (AD). Herein, we synthesised 19 novel pyranone-carbamate derivatives and evaluated their activities against cholinesterases and neuroinflammation. The optimal compound <b>7p</b> exhibited balanced BuChE inhibitory activity (eqBuChE IC<sub>50</sub> = 4.68 nM; huBuChE IC<sub>50</sub> = 9.12 nM) and anti-neuroinflammatory activity (NO inhibition = 28.82% at 10 μM, comparable to hydrocortisone). Enzyme kinetic and docking studies confirmed compound <b>7p</b> was a mix-type BuChE inhibitor. Additionally, compound <b>7p</b> displayed favourable drug-likeness properties in silico prediction, and exhibited high BBB permeability in the PAMPA-BBB assay. Compound <b>7p</b> had good safety in vivo as verified by an acute toxicity assay (LD<sub>50</sub> > 1000 mg/kg). Most importantly, compound <b>7p</b> effectively mitigated cognitive and memory impairments in the scopolamine-induced mouse model, showing comparable effects to Rivastigmine. Therefore, we envisioned that compound <b>7p</b> could serve as a promising lead compound for treating AD.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2313682"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10878344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139741200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-07-29 DOI: 10.1080/14756366.2024.2374156
{"title":"Correction.","authors":"","doi":"10.1080/14756366.2024.2374156","DOIUrl":"10.1080/14756366.2024.2374156","url":null,"abstract":"","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2374156"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity. 设计和合成具有广谱抗增殖活性的强效 JAK/HDAC 双抑制剂三唑吡啶衍生物。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-10-08 DOI: 10.1080/14756366.2024.2409771
Zhengshui Xu, Changchun Ye, Xingjie Wang, Ranran Kong, Zilu Chen, Jing Shi, Xin Chen, Shiyuan Liu
{"title":"Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity.","authors":"Zhengshui Xu, Changchun Ye, Xingjie Wang, Ranran Kong, Zilu Chen, Jing Shi, Xin Chen, Shiyuan Liu","doi":"10.1080/14756366.2024.2409771","DOIUrl":"10.1080/14756366.2024.2409771","url":null,"abstract":"<p><p>A series of triazolopyridine-based dual JAK/HDAC inhibitors were rationally designed and synthesised by merging different pharmacophores into one molecule. All triazolopyridine derivatives exhibited potent inhibitory activities against both targets and the best compound 4-(((5-(benzo[<i>d</i>][1, <i>3</i>]dioxol-5-yl)-[1, 2, 4]triazolo[1, 5-<i>a</i>]pyridin-2-yl)amino)methyl)-<i>N</i>-hydroxybenzamide (19) was dug out. 19 was proved to be a pan-HDAC and JAK1/2 dual inhibitor and displayed high cytotoxicity against two cancer cell lines MDA-MB-231 and RPMI-8226 with IC<sub>50</sub> values in submicromolar range. Docking simulation revealed that 19 fitted well into the active sites of HDAC and JAK proteins. Moreover, 19 exhibited better metabolic stability in vitro than SAHA. Our study demonstrated that compound 19 was a promising candidate for further preclinical studies.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2409771"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies. 与苊烯酮相连的新型咪唑-2-硫酮作为双重 DNA 中间体和拓扑异构酶 II 抑制剂:结构优化、对接和细胞凋亡研究。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-03-15 DOI: 10.1080/14756366.2024.2311818
Asmaa H Mohamed, Mohammed B Alshammari, Ashraf A Aly, Kamal U Sadek, Akil Ahmad, Eman A Aziz, Amira F El-Yazbi, Eman J El-Agroudy, Marwa E Abdelaziz
{"title":"New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies.","authors":"Asmaa H Mohamed, Mohammed B Alshammari, Ashraf A Aly, Kamal U Sadek, Akil Ahmad, Eman A Aziz, Amira F El-Yazbi, Eman J El-Agroudy, Marwa E Abdelaziz","doi":"10.1080/14756366.2024.2311818","DOIUrl":"10.1080/14756366.2024.2311818","url":null,"abstract":"<p><p>In this article, a new series of 2-((3,5-disubstituted-2-thioxo-imidazol-1-yl)imino)acenaphthylen-1(2<i>H</i>)-ones were synthesized. Imidazole-2-thione with acenaphthylen-one gave a hybrid scaffold that integrated key structural elements essential for DNA damage <i>via</i> direct DNA intercalation and inhibition of the topoisomerase II enzyme. All the synthesized compounds were screened to detect their DNA damage using a terbium fluorescent probe. Results demonstrated that 4-phenyl-imidazoles <b>5b</b> and <b>5e</b> in addition to 4-(4-chlorophenyl)imidazoles <b>5h</b> and <b>5j</b> would induce detectable potent damage in ctDNA. The four most potent compounds as DNA intercalators were further evaluated for their antiproliferative activity against HepG2, MCF-7 and HCT-116 utilizing the MTT assay. The highest anticancer activity was recorded with compounds <b>5b</b> and <b>5h</b> against the breast cancer cell line MCF-7 which were 1.5- and 3- folds more active than <b>doxorubicin</b>, respectively. Therefore, imidazole-2-thione tethered acenaphthylenone derivatives can be considered as promising scaffold for the development of effective dual DNA intercalators and topoisomerase II inhibitors.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2311818"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a multi-targeted chemotherapeutic approach based on G-quadruplex stabilisation and carbonic anhydrase inhibition. 开发基于 G-四叉链稳定和碳酸酐酶抑制的多靶点化疗方法。
IF 5.6 2区 医学
Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2024-12-01 Epub Date: 2024-06-18 DOI: 10.1080/14756366.2024.2366236
Alessio Nocentini, Anna Di Porzio, Alessandro Bonardi, Carla Bazzicalupi, Andrea Petreni, Tarita Biver, Silvia Bua, Simona Marzano, Jussara Amato, Bruno Pagano, Nunzia Iaccarino, Stefano De Tito, Stefano Amente, Claudiu T Supuran, Antonio Randazzo, Paola Gratteri
{"title":"Development of a multi-targeted chemotherapeutic approach based on G-quadruplex stabilisation and carbonic anhydrase inhibition.","authors":"Alessio Nocentini, Anna Di Porzio, Alessandro Bonardi, Carla Bazzicalupi, Andrea Petreni, Tarita Biver, Silvia Bua, Simona Marzano, Jussara Amato, Bruno Pagano, Nunzia Iaccarino, Stefano De Tito, Stefano Amente, Claudiu T Supuran, Antonio Randazzo, Paola Gratteri","doi":"10.1080/14756366.2024.2366236","DOIUrl":"10.1080/14756366.2024.2366236","url":null,"abstract":"<p><p>A novel class of compounds designed to hit two anti-tumour targets, G-quadruplex structures and human carbonic anhydrases (hCAs) IX and XII is proposed. The induction/stabilisation of G-quadruplex structures by small molecules has emerged as an anticancer strategy, disrupting telomere maintenance and reducing oncogene expression. hCAs IX and XII are well-established anti-tumour targets, upregulated in many hypoxic tumours and contributing to metastasis. The ligands reported feature a berberine G-quadruplex stabiliser scaffold connected to a moiety inhibiting hCAs IX and XII. <i>In vitro</i> experiments showed that our compounds selectively stabilise G-quadruplex structures and inhibit hCAs IX and XII. The crystal structure of a telomeric G-quadruplex in complex with one of these ligands was obtained, shedding light on the ligand/target interaction mode. The most promising ligands showed significant cytotoxicity against CA IX-positive HeLa cancer cells in hypoxia, and the ability to stabilise G-quadruplexes within tumour cells.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2366236"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信